AURKB and leukemia: In addition, the synergistic effects of MLT in combination with new agents (recently approved for clinical use or still in clinical trials) such as everolimus (mTOR inhibitor) or barasertib (selective inhibitors of aurora B kinase) on the cytotoxicity and induction of leukaemia lymphocyte apoptosis have been described [21].